Wird geladen...
A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial
Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-vs.-host disease (GVHD) and non-relapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T-replete HLA-mismatched HSCT, and may also benefit myelo...
Gespeichert in:
Veröffentlicht in: | Biol Blood Marrow Transplant |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
2015
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4604028/ https://ncbi.nlm.nih.gov/pubmed/26055298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.05.027 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|